1. A Zeb1/MtCK1 metabolic axis controls osteoclast activation and skeletal remodeling. (27th February 2023) Authors: Zhu, Lingxin; Tang, Yi; Li, Xiao‐Yan; Kerk, Samuel A; Lyssiotis, Costas A; Feng, Wenqing; Sun, Xiaoyue; Hespe, Geoffrey E; Wang, Zijun; Stemmler, Marc P; Brabletz, Simone; Brabletz, Thomas; Keller, Evan T; Ma, Jun; Cho, Jung‐Sun; Yang, Jingwen; Weiss, Stephen J Journal: EMBO journal Issue: Volume 42:Number 7(2023) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. LW106, a novel indoleamine 2, 3‐dioxygenase 1 inhibitor, suppresses tumour progression by limiting stroma‐immune crosstalk and cancer stem cell enrichment in tumour micro‐environment. (3rd June 2018) Authors: Fu, Rong; Zhang, Yi‐Wei; Li, Hong‐Mei; Lv, Wen‐Cong; Zhao, Li; Guo, Qing‐Long; Lu, Tao; Weiss, Stephen J; Li, Zhi‐Yu; Wu, Zhao‐Qiu Journal: British journal of pharmacology Issue: Volume 175:Number 14(2018) Page Start: 3034 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗